ARTICLE | Clinical News

Gruenenthal's cebranopadol meets Phase III pain endpoint

September 30, 2016 7:00 AM UTC

Gruenenthal Group (Aachen, Germany) said once-daily cebranopadol ( GRT6005) met the primary endpoint of a Phase III study to treat cancer-related pain. The company said cebranopadol was non-inferior, as well as superior, to twice-daily prolonged-release morphine sulfate based on statistically significant improvements on the primary endpoint, which assessed average amount of daily rescue medication over the last two weeks of the trial's maintenance phase (p<0.05).

The company said cebranopadol was well-tolerated, with side effects comparable to morphine sulfate. Results from the study were presented at the World Congress on Pain in Yokohama, Japan. ...